Allergan to file drug application for eyelash growth stimulant

Irvine, CA-Allergan Inc. intends to file a new drug application with the FDA by the end of the third quarter of this year for bimatoprost, a synthetic prostaglandin analog, as a treatment to stimulate eyelash growth.

Irvine, CA-Allergan Inc. intends to file a new drug application with the FDA by the end of the third quarter of this year for bimatoprost, a synthetic prostaglandin analog, as a treatment to stimulate eyelash growth.

The company said it has completed its clinical trial program demonstrating the drug’s patented formulation results in significant eyelash growth when applied directly to the base of the eyelashes.

“We are pleased with the results of our program and believe this innovative product, if approved, could meet a significant and currently unmet demand in the medical aesthetic marketplace,” said Scott Whitcup, MD, Allergan’s vice president, research and development.

If approved by the FDA for eyelash growth, the company estimates global peak sales for the drug could exceed $500 million per year.  

“The development of this innovative product stems from our 60-year expertise and leadership in prescription eye-care products,” said David E.I. Pyott, Allergan’s chairman of the board and chief executive officer.